Vanda Pharmaceuticals Inc. (VNDA) has a significant regulatory catalyst to watch tomorrow.The company's atypical antipsychotic Fanapt, proposed for the expanded use in treating bipolar I disorder, awaits the FDA decision on April 2, 2024.Fanapt is already approved in the U.S. for the treatment of schizophrenia in adults.Though bipolar disorder and schizophrenia are both mental health conditions, t...
For comments and feedback contact: editorial@rttnews.com
May 22, 2026 14:46 ET Minutes of the latest Fed policy session was the highlight of the week along with survey data on the U.S. housing market. In Europe, survey data signaled the trends in the euro area private sector. Further, consumer price inflation data from the U.K. was in focus. In Asia, various economic indicators from China drew attention to the health of the economy.